Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ArcticZymes Technologies Share Issue/Capital Change 2021

Dec 10, 2021

3538_rns_2021-12-10_e146b9f5-38f7-46a5-ba5d-c467e723d26b.html

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

ArcticZymes Technologies ASA: Increase of share capital related to exercise of options

ArcticZymes Technologies ASA: Increase of share capital related to exercise of options

Tromsø, Norway, 10[th] December 2021 - ArcticZymes Technologies ASA (OSE: AZT)

will increase its share capital related to exercise of options.

The Board of Directors in ArcticZymes Technologies ASA) (OSE: AZT) have to

fulfil the Company's obligations under the share option agreements and in

accordance with the authorization granted by the general meeting on 20 May 2021,

resolved to increase the Company's share capital by NOK 200,000 by issuance of

200,000 new shares. The options have a strike price of NOK 8.00 per share.

The capital increase is expected to be registered within 7 days, and following

the issuance of the new shares. The issued share capital of ArcticZymes

Technologies ASA will be NOK 50,371,390 consisting of 50,371,390 shares, each

with a par value of NOK 1.00 after the capital increase is registered.

The information included in this announcement is such that the Company is

required to disclose in accordance with the EU Market Abuse Regulation (MAR)

section and 19 and section 5-12 of the Norwegian Securities Trading Act.

The announcement is made by CFO Børge Sørvoll, 10 December 2021, at 1258 CET.

For more information, please contact:

Børge Sørvoll

CFO

+47 95290187

[email protected]

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the

development, manufacturing and commercialization of novel recombinant enzymes

for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]

ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies

in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at

the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large

portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.